LIVN

LivaNova PLC

Healthcare


Presented:03/25/2022
Price:$78.26
Cap:$4.17B
Current Price:$53.67
Cap:$2.91B

Presented

Date03/25/2022
Price$78.26
Market Cap$4.17B
Ent Value$4.74B
P/E RatioN/A
Book Value$24.31
Div Yield0%
Shares O/S53.26M
Ave Daily Vol316,080
Short Int4.71%

Current

Price$53.67
Market Cap$2.91B
LivaNova Plc is a global medical technology company, which engages in the development and delivery of therapeutic solutions for the benefit of patients, healthcare professionals, and healthcare systems. It operates through the Cardiovascular and Neuromodulation segments. The Cardiovascular segment develops, produces, and sells cardiopulmonary products, heart valves, and circulatory support products. The Neuromodulation segment designs, develops, and markets Neuromodulation therapy for the treatment of drug-resistant epilepsy, difficult-to-treat depression (DTD), and obstructive sleep apnea. The company was founded in 1987 and is headquartered in London, the United Kingdom.

Publicly traded companies mentioned herein: LivaNova PLC (LIVN)

Highlights

The presenter is long shares of LivaNova PLC (LIVN), which has a $4.3B EV and was formed in 2015 following the merger between Cyberonics and Sorin. The core business is earning ~$4 per share, and its $80 share price implies a 20x earnings multiple. That valuation seems reasonable for the business as it stands today, but investors are also receiving LIVN’s pipeline for free, which is the aspect he is most excited about. By the end of 2023, he reaches a target EV of close to $9B, with roughly half coming from its pipeline. 

  • Signing up and creating account with us unlocks this content for you. Contact us today for full access to DeMatteo Research and more.

  • Signing up and creating account with us unlocks this content for you. Contact us today for full access to DeMatteo Research and more.

Request access to DeMatteo Research for full access

Request Access

Already have an account?

Idea Discussion

Commentor 1 - 2 weeks ago

Signing up and creating account with us, unlocks this content for you. Contact us today for full access to DeMatteo Research and more.

Commentor 1 - 2 weeks ago

Signing up and creating account with us, unlocks this content for you. Contact us today for full access to DeMatteo Research and more.

Idea Discussions display submitted commentary from our investor community.

To read and participate in the discussion with the presenter and investor base, request access to DeMatteo

Request Access

Already have an account?

An error occurred loading this content. Try again later or contact us.